Cephalon moved to further augment its cancer treatment pipeline by acquiring ChemGenex for its late phase drug Omapro. Omapro is for the treatment of chronic myeloid leukemia (CML). Cephalon will pay $153 million to acquire the rest of ChemGenex's stock in this transaction. Omapro is expected to see FDA approval later this year. See Fierce Biotech.
Posted by Bruce Lehr March 29th 2011.
Comments